Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$41.1M
Filings
396
Firms Hired
8
Active Period
2007–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month".
2026 · third_quarter · Firm: THEGROUP DC, LLC
H.Res.1090, Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month" Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.Res.1090
Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month".
2026 · third_quarter · Firm: THEGROUP DC, LLC
H.Res.1090, Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month" Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.Res.1090
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
2026 · third_quarter · Firm: TODD STRATEGY GROUP
Women's health and menopause. Issues related to P.L.119-21 (H.R. 1): One Big Beautiful Bill Act. Eye screening and access.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1
PSA Screening for HIM Act
2026 · second_quarter · Firm: ASTELLAS PHARMA US, INC.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $510,000 · Firm income: —
Matched citations: H.R. 1300
PSA Screening for HIM Act
2026 · second_quarter · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $510,000 · Firm income: —
Matched citations: H.R. 1300
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $510,000 · Firm income: —
Matched citations: S. 297
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $510,000 · Firm income: —
Matched citations: S. 297
Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month".
2026 · second_quarter · Firm: THEGROUP DC, LLC
H.Res.1090, Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month" Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.Res.1090
Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month".
2026 · second_quarter · Firm: THEGROUP DC, LLC
H.Res.1090, Expressing support for the designation of February 2026 as "Low Vision and Vision Impairment Awareness Month" Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.Res.1090
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
PSA Screening for HIM Act
2026 · first_quarter · Firm: ASTELLAS PHARMA US, INC.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $590,000 · Firm income: —
Matched citations: H.R. 1300
PSA Screening for HIM Act
2026 · first_quarter · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $590,000 · Firm income: —
Matched citations: H.R. 1300
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $590,000 · Firm income: —
Matched citations: S. 297
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $590,000 · Firm income: —
Matched citations: S. 297
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
PSA Screening for HIM Act
2025 · fourth_quarter · Firm: ASTELLAS PHARMA US, INC.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $980,000 · Firm income: —
Matched citations: H.R. 1300
PSA Screening for HIM Act
2025 · fourth_quarter · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $980,000 · Firm income: —
Matched citations: H.R. 1300
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $980,000 · Firm income: —
Matched citations: S. 297
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $980,000 · Firm income: —
Matched citations: S. 297
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
H.R. 1300, PSA Screening for HIM Act Prostate-Specific Antigen Screening for High-risk Insured Men Act Issues related to the treatment of menopause and womens health at mid-life.
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1300
PSA Screening for HIM Act
2025 · third_quarter · Firm: ASTELLAS PHARMA US, INC.
H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.
Client expense: $850,000 · Firm income: —
Matched citations: H.R. 1300
PSA Screening for HIM Act
2025 · third_quarter · Firm: ASTELLAS PHARMA US, INC.
Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).
Client expense: $850,000 · Firm income: —
Matched citations: H.R. 1300
Source: Senate LDA